- Home
- ACON vs INM Comparison
ACON vs INM Comparison
Compare ACON & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACON | INM |
|---|---|---|
| Founded | 2008 | 1981 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4M | 3.7M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACON | INM |
|---|---|---|
| Price | $5.27 | $1.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | 104.5K | ★ 154.8K |
| Earning Date | 11-12-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $67,483.00 | ★ $4,798,116.00 |
| Revenue This Year | $71.77 | N/A |
| Revenue Next Year | $80.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.91 | N/A |
| 52 Week Low | $4.32 | $1.03 |
| 52 Week High | $2,156.31 | $8.27 |
Technical Indicators
Market Signals| Indicator | ACON | INM |
|---|---|---|
| Relative Strength Index (RSI) | 42.79 | 40.03 |
| Support Level | $4.32 | $1.03 |
| Resistance Level | $6.40 | $1.19 |
| Average True Range (ATR) | 0.40 | 0.08 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 45.79 | 32.31 |
Price Performance
Historical ComparisonAbout ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.